0001209191-17-051252.txt : 20170905
0001209191-17-051252.hdr.sgml : 20170905
20170905160226
ACCESSION NUMBER: 0001209191-17-051252
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20170831
FILED AS OF DATE: 20170905
DATE AS OF CHANGE: 20170905
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Walsh Jeffrey T.
CENTRAL INDEX KEY: 0001578251
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-35966
FILM NUMBER: 171068735
MAIL ADDRESS:
STREET 1: C/O BLUEBIRD BIO, INC.
STREET 2: 840 MEMORIAL DRIVE
CITY: CAMBRIDGE
STATE: MA
ZIP: 02139
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: bluebird bio, Inc.
CENTRAL INDEX KEY: 0001293971
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
IRS NUMBER: 000000000
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 60 BINNEY STREET
CITY: CAMBRIDGE
STATE: MA
ZIP: 02142
BUSINESS PHONE: 339-499-9300
MAIL ADDRESS:
STREET 1: 60 BINNEY STREET
CITY: CAMBRIDGE
STATE: MA
ZIP: 02142
FORMER COMPANY:
FORMER CONFORMED NAME: Genetix Pharmaceuticals Inc
DATE OF NAME CHANGE: 20040616
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2017-08-31
0
0001293971
bluebird bio, Inc.
BLUE
0001578251
Walsh Jeffrey T.
C/O BLUEBIRD BIO, INC.
60 BINNEY STREET
CAMBRIDGE
MA
02142
0
1
0
1
Chief Financial
and Strategy Officer
Common Stock
2017-08-31
4
M
0
12000
5.5004
A
39305
D
Common Stock
2017-08-31
4
S
0
12000
125.0076
D
27305
D
Stock Option (right to buy)
5.5004
2017-08-31
4
M
0
12000
0.00
D
2023-01-16
Common Stock
12000
72385
D
The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 23, 2016.
The range of prices for the transaction reported on this line was $125.00 to $125.15. The average weighted price was $125.0076. The reporting person will provide, upon request by the SEC, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price.
This option to purchase shares of our common stock granted on January 16, 2013 with performance-based vesting criteria that were met as of January 1, 2013. The shares underlying these options vested as follows: 25% vested on January 1, 2014, with the remainder of the shares vesting in equal monthly installments over the following three years.
/s/ Jason F. Cole, Attorney-in-Fact
2017-09-05